[Edaily Reporter KIM SAE-MI ] SK BIOPHARMACEUTICALS(326030)has set out to strengthen its commercialization capabilities to expand the direct sales system it has established in the U.S. from a single product—cenobamate—to multiple products.

SK BIOPHARMACEUTICALS announced on the 2nd that its U.S. subsidiary, SK Life Sciences, held the “2026 Plan of Action” (POA) meeting in Chicago, Illinois, from the 29th of last month to the 1st of this month (local time).

The POA is an event where sales personnel from pharmaceutical and biotech companies gather to review performance and market conditions and share future execution strategies. Since launching the new epilepsy drug cenobamate (U.S. brand name Xcopri) in 2020, SK BIOSCIENCE has held a National Sales Meeting (NSM) every year at the beginning of the year to share annual sales strategies and goals, and has reviewed performance at the POA in the second half of the year.

This meeting was held under the same “We Will” theme as the NSM held last February. The aim is to strengthen employees’ proactive execution and growth based on the “One Team” strategy, in which the headquarters and the U.S. subsidiary operate under the same direction and priorities.

Approximately 160 people, primarily local sales personnel in the U.S., attended the event. Participants reviewed first-half performance and market changes and discussed sales strategies for the second half to sustain the growth momentum of cenobamate.

They also discussed plans to leverage the existing U.S. sales organization and commercialization infrastructure in preparation for the introduction of new products and portfolio expansion.

SK BIOPHARMACEUTICALS is pursuing a “multi-product” strategy to expand the direct sales capabilities in the U.S.—established through cenobamate—to new products. The plan is to secure new products that can leverage local commercialization capabilities, such as sales, marketing, and market access, to enhance the efficiency of the existing sales organization and expand its product portfolio in the epilepsy field.

The company is also pursuing a growth strategy specifically for cenobamate. It is working to expand dosage forms—such as oral suspensions—develop treatments for pediatric and adolescent patients, and broaden the indication to include primary generalized tonic-clonic seizures (PGTC).

Lee Dong-hoon, President of SK BIOPHARMACEUTICALS, stated, “The sales organization we built directly in the U.S. is the strongest operational foundation that has driven Senobamate’s growth,” adding, “Now, the key is not to limit this momentum to Senobamate alone, but to extend it to our next products and new growth opportunities.” He added, “By moving faster and executing more vigorously as a ‘single team’ between our headquarters and our U.S. operations, we will sustain Cenobamate’s growth while turning the multi-product era into tangible results.”